Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 |
| Net income | $8.86M | $8.08M | $11.1M | -$8.05M | -$9.13M | -$38.3M | -$22.7M | -$29.3M | -$21.7M | -$30.1M |
| EPS (diluted) | — | — | — | — | — | — | — | -$2.47 | -$1.21 | -$0.63 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.15M | -$8.02M | -$9.85M | -$6.33M | -$7.93M | -$18.9M | -$20.4M | -$12.0M | -$14.7M | -$27.6M |
| Capital expenditures | — | — | — | — | — | — | — | $79.2K | $57.9K | $76.1K |
| Free cash flow | — | — | — | — | — | — | — | -$12.0M | -$14.8M | -$27.7M |
| Share buybacks | — | — | — | — | — | — | — | $24.8K | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.16M | $6.59M | $5.97M | $3.72M | $2.39M | $10.5M | $11.8M | $3.67M | $12.7M | $3.62M |
| Total assets | $6.36M | $7.91M | $7.07M | $4.04M | $2.94M | $13.5M | $15.9M | $4.36M | $20.0M | $27.4M |
| Total liabilities | $1.50M | $1.33M | $1.64M | $2.07M | $2.67M | $2.96M | $4.15M | $5.92M | $5.37M | $6.42M |
| Long-term debt | $694K | $28.1K | $1.12K | — | — | — | — | — | — | — |
| Shareholders' equity | $4.86M | $6.58M | $5.44M | $1.97M | $263K | $10.6M | $12.3M | -$1.56M | $14.6M | $20.9M |
| Retained earnings | -$32.2M | -$41.1M | -$52.4M | -$60.6M | -$69.7M | -$111M | -$136M | -$88.5M | -$111M | -$141M |
| Shares (wtd avg diluted) | 10.9M | 12.0M | 2.09M | 2.57M | 10.4M | 25.9M | 974K | 11.9M | 18.7M | 47.9M |
Every figure is extracted from TuHURA Biosciences, Inc./NV’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.